Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

IRVINE, Calif., March 31 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today reported financial results for the fourth quarter and full year ended December 31, 2008. Financial information presented represents the consolidated results of IDM Pharma, Inc. and its subsidiary, IDM Pharma S.A.

Total revenues in the quarter ended December 31, 2008 were $0.3 million, and net loss was $1.8 million or $0.07 per share for the quarter. Total revenues for the year ended December 31, 2008 were $3.1 million, and net loss was $18.6 million or $0.74 per share for the year. Cash and cash equivalents were $12.8 million as of December 31, 2008 compared to $18.4 million on September 30, 2008 and $28.4 million on December 31, 2007. In order to focus on those areas we believe can provide the most near term value to our stockholders and to ensure we have adequate cash to complete our review of strategic options for the Company, we are concentrating our near-term efforts on certain MEPACT pre-launch commercial activities in Europe and the review of such strategic options, including merger or acquisition opportunities, which may involve a change in control of our company. Consequently, we have placed the U.S. mifamurtide NDA amendment submission on hold until we complete our strategic review, which will allow us to operate into the third quarter of 2009. We have engaged JMP Securities, an investment bank, to advise us in exploring alternatives available to us with respect to a possible merger or acquisition transaction.

"2008 was a significant year for the Company with December's recommendation for approval of MEPACT for the treatment of osteosarcoma in Europe and the formal approval of the centralized marketing authorization following in early March of 2009," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "W
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)...  AACC, a global scientific and medical professional ... is pleased to announce that the impact factor ... increased to 7.9 in the 2014 Thomson Reuters ... Chemistry in the top 3% of all ... the research it publishes on laboratory medicine and ...
(Date:6/29/2015)... 2015 According to a new market ... Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), by ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... from $107.56 Million in 2015, at a CAGR of 17.89%. ... 67 F igures spread through 125 ...
(Date:6/29/2015)... 2015   For the seventh year running, Across Health ... overall digital maturity called the Multichannel Maturometer . ... not maturing fast enough. While it,s true that technology ... overall and customers are increasingly "digital natives", pharma still ... engagement.  ...
(Date:6/26/2015)... CITY, Kan. , June 26, 2015 ... PETX ), a pet therapeutics company ... of innovative biopharmaceutical products for companion animals, ... field effectiveness study of capromorelin (AT-002), the ... dogs.  Capromorelin is a small molecule that ...
Breaking Biology Technology:AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5
... , Data Reported at the 2010 ASCO ... Both Time to Tumor Progression and Overall Survival in ... Arm , QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ ... AEZ) (the "Company"), a late-stage drug development company specialized ...
... thin films for semiconductors in electronic devices, layers of atoms ... materials grow smooth crystals, others tend to develop bumps and ... In the online edition of the journal Science ... how atoms arrange themselves into thin films. Led by assistant ...
... As ... bright spot in terms of employment growth. But that was offset by a rough ride for ... pharmaceutical companies going into 2010 are any indication, the trouble isn,t over just yet. , ... (Vocus) January 21, 2010 -- As one of ...
Cached Biology Technology:Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 2Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 3Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 4Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 5Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 6Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 7Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 8Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer 9Watching crystals grow provides clues to making smoother, defect-free thin films 2The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 2The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 3The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs 4
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... 2015 from previously communicated that it will amount to at ... 390 MSEK. Due to the rapid increase in market growth ... from the previously communicated guidance that revenue for 2015 will ... 2015 will amount to approximately 2,200 MSEK. Due ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
(Date:6/9/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ) has ... & Touchless Sensing Market by Technology (Touch-based & ... (Biometric & Sanitary Equipment) & by Geography - ... offering. The total gesture recognition and ... 23.55 Billion by 2020 at a high CAGR ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... bugs grow in intensive care units to develop a ... MRSA and other superbugs in the environment, scientists heard ... General Microbiologys 162nd meeting being held this week at ... a standard sampling regime to take swabs from sinks, ...
... deadliest diseases, caused by the Ebola virus, may finally ... have successfully tested several Ebola vaccines in primates and ... Dr Anthony Sanchez, from the Centers for Disease ... overview of Ebola vaccine development today (Monday 31 March ...
... Multi-Modal Biometric Identification Solution ... and Interoperability, SCHAUMBURG, Ill., March 28 ... it has been selected by the West Virginia,State ... (BIS). Motorola,s latest BIS solution features new algorithms ...
Cached Biology News:MRSA in hospital intensive care -- what's growing where? 2Vaccine for Ebola virus 2Motorola Biometric Identification System Selected by West Virginia State Police 2
...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... skirted micro test tubes are used to ... these tubes have uniform walls for uniform ... separate O-ring screw caps. The O-rings are ... an operating range from -55 to 150 ...
Biology Products: